Keyword: Oxford University

AstraZeneca and Oxford BioMedica have inked a deal to produce commercial and clinical supply of the University of Oxford's COVID-19 shot hopeful.

CanSino Bio, Moderna and a collaboration between Oxford Univeristy and AstraZeneca are frontrunners, but they all face hurdles shared and unique.

Novartis CEO Vas Narasimhan said a potential COVID-19 vaccine could take until the end of 2021 despite high hopes from some shot developers.

Moderna and Lonza struck a deal to build out manufacturing for a potential mRNA-based coronavirus vaccine that's currently in phase 1 trials.

AstraZeneca will own global manufacturing and distribution rights to the University of Oxford's adenovirus-based COVID-19 vaccine hopeful

In its latest development deal, the outbreak readiness group CEPI has awarded J&J and Oxford University $14.6 million for work on a MERS vaccine.

The partnership aims to make the production of vaccines that use adenovirus as vectors more cost-effective and contamination-free.

Here's some other vaccine news of note for the week.

The £20 million series A backed by GV will help Vaccitech develop an MVA-vectored universal flu vaccine currently in phase 2.

Researchers in England are kicking off the world's first large human trial of a "universal" influenza shot.